drugset

drugset / Trial / NCT04908280

Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus

NCT04908280 ↗

Phase 2 Completed 10 enrolled University of Rochester Incyte Corporation · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the potential efficacy of topical ruxolitinib for the treatment of discoid lupus erythematosus (DLE)

Timeline

Start: 2022-05-04
Primary completion: 2024-03-04
Completion: 2024-03-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ruxolitinib	Small molecule	1.5 %	Topical

Indications